arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

RxSight, Inc.

RXST
$4.87 ▼ -0.07 (-1.42%) at close
Industrials ·Ophthalmic Goods ·USOphthalmic Goods
25 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
18
Health
Poor
Bearish
auto_awesome

Analytical Summary

RxSight, Inc. faces fundamental challenges with weakness in Profit Margin (%) and Operating Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $202.1M
Dividend Yield —
Revenue Growth 0.3% ↗
Op. Margin -40.8% ↗
ROIC -5.3% ↗
FCF / Share $-0.28 →
Trailing P/E —
Price / Book 0.8x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Sep 23, 2026.

25-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$33.74M
— +0.3% —
Net Income Profit after all expenses
$-15.88M
↓ -93.9% —
Operating Margin Operating profit as % of sales
-40.8%
↑ +29.3% 7th
FCF / Share Free cash flow per share
$-0.28
↓ -90.9% —
Long-Term Debt Long-term obligations
$0.00
↓ -100.0% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability ↑
8
Returns ↑
31
Financial Health ↓
2
Cash Quality ↓
40

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 6 years · 25 quarters